Figure 2: (Left) Central macular thickness (CMT) reduction (%) and (Right) Improvement in the logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) following intravitreal bevacizumab (IVB) in diabetic macular edema (DME) groups.Diffuse retinal thickening (SDRT), cystoids macular edema (CME),and combined DME patients had a greater reduction in CMT than serous retinal detachment (SRD) patients. There were no statistical differences among the SDRT, CME, or Combined groups (P=0.498,Kruskal-Wallis test). The percent reduction in the SRD group was significantly lower than that in the combined group (P=0.014,Mann-Whitney test). Improvements over preoperative values were statistically significant in all groups (P<0.001, Wilcoxon signed rank test). No statistically significant differences in logMAR VA improvement were found between the four groups (P=0.213,Kruskal-Wallis test). The horizontal bar indicates the mean percent reduction and logMAR VA improvement in the DME groups.